News | September 16, 2014

Minneapolis Heart Institute Announces Its First Implant of Portico Aortic Heart Valve System

St. Jude Medical Portico TAVR System Minneapolis Heart Institute Implant Trial

September 16, 2014 — The Minneapolis Heart Institute Foundation (MHIF) announced its first implant of the Portico Re-sheathable Transcatheter Aortic Valve System, developed by St. Jude Medical. With this, MHIF became the first hospital in the Midwest and the third in the country to implant the Portico valve as part of the Portico Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO clinical trial).

The Portico heart valve is used during transcatheter aortic valve replacement (TAVR) procedures, during which the valve is delivered via a catheter through a transfemoral artery or alternative access point. This eliminates the need for invasive open-heart surgery. As such, the PORTICO trial is enrolling patients who are considered to have a high or an extreme surgical risk that has eliminated them from consideration for open-heart surgery.

The Portico valve is the first transcatheter aortic valve that can be completely resheathed (brought back into the delivery catheter), repositioned at the implant site, or retrieved after partial deployment and prior to final implantation. This helps to ensure accurate placement of the valve, ultimately simplifying the implant procedure and minimizing procedural risk for the patient. Further, the valve is positioned in the patient’s heart as it continues to beat, which alleviates the need for cardiopulmonary bypass.

MHIF, with its pursuits and commitment to the latest innovations in patient care, played an integral role in this development. Vibhu Kshettry, MHIF researcher and cardiovascular thoracic surgeon at Minneapolis Heart Institute at Abbott Northwestern Hospital (MHI), led efforts during this first implantation and described the Portico system as an “ongoing improvement in current percutaneous technology and a step forward in acute management of this high-risk population.” Wesley Pedersen, MHIF researcher and cardiologist at MHI, worked in conjunction with Kshettry on this first case and noted, “My preliminary experience with this system fills in several gaps not currently addressed in transcatheter treatment of aortic stenosis - those being ease of use, minimization of paravalvular leak, and need for permanent pacemaker.”

For more information: mplsheart.org

Related Content

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology| January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology| January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology| November 07, 2017
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and c
Videos | Heart Valve Technology| November 07, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state o
Overlay Init